These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34835288)

  • 21. SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection.
    Kang YM; Choe KW; Lee KD; Kim KN; Kim MJ; Lim J
    J Korean Med Sci; 2021 Sep; 36(35):e250. PubMed ID: 34490757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
    Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
    CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers.
    Bayart JL; Douxfils J; Gillot C; David C; Mullier F; Elsen M; Eucher C; Van Eeckhoudt S; Roy T; Gerin V; Wieers G; Laurent C; Closset M; Dogné JM; Favresse J
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity.
    Morgiel E; Szmyrka M; Madej M; Sebastian A; Sokolik R; Andrasiak I; Chodyra M; Walas-Antoszek M; Korman L; Świerkot J
    Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer.
    Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Jung EJ; Woo H; Seo YB; Park JJ; Kim HS
    Diagnostics (Basel); 2021 Dec; 12(1):. PubMed ID: 35054251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-SARS-CoV-2S Antibody Levels in Healthcare Workers 10 Months after the Administration of Two BNT162b2 Vaccine Doses in View of Demographic Characteristic and Previous COVID-19 Infection.
    Wolszczak-Biedrzycka B; Bieńkowska A; Zaborowska JE; Smolińska-Fijołek E; Biedrzycki G; Dorf J
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients.
    Berar-Yanay N; Freiman S; Shapira M; Saffoury A; Elemy A; Hamze M; Elhaj M; Zaher M; Matanis L; Armaly ZA
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty
    Held J; Esse J; Tascilar K; Steininger P; Schober K; Irrgang P; Alsalameh R; Tenbusch M; Seggewies C; Bogdan C
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection.
    Vicenti I; Gatti F; Scaggiante R; Boccuto A; Zago D; Basso M; Dragoni F; Zazzi M; Parisi SG
    Int J Infect Dis; 2021 Jul; 108():176-178. PubMed ID: 34022329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination.
    Lukaszuk K; Kiewisz J; Rozanska K; Dabrowska M; Podolak A; Jakiel G; Woclawek-Potocka I; Lukaszuk A; Rabalski L
    Vaccines (Basel); 2021 Jul; 9(8):. PubMed ID: 34451965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.
    Assis R; Jain A; Nakajima R; Jasinskas A; Khan S; Palma A; Parker DM; Chau A; ; Obiero JM; Tifrea D; Leung A; Grabar C; Muqolli F; Khalil G; Escobar JC; Ventura J; Davies DH; Albala B; Boden-Albala B; Schubl S; Felgner PL
    NPJ Vaccines; 2021 Nov; 6(1):132. PubMed ID: 34737318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population.
    Papadopoli R; De Sarro C; Palleria C; Gallelli L; Pileggi C; De Sarro G
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections.
    Arsuffi S; Sansone E; Focà E; Storti S; Diaferia T; Bonfanti C; Terlenghi L; Caruso A; Sala E; Castelli F; De Palma G; Quiros-Roldan E
    iScience; 2023 May; 26(5):106716. PubMed ID: 37152764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination.
    Dentone C; Fenoglio D; Ponzano M; Cerchiaro M; Altosole T; Franciotta D; Portunato F; Mikulska M; Taramasso L; Magnasco L; Uras C; Magne F; Ferrera F; Scavone G; Signori A; Vena A; Visconti V; Filaci G; Sette A; Grifoni A; Di Biagio A; Bassetti M
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.